These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26417646)

  • 21. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
    Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conditional probability of reclassification in an active surveillance program for prostate cancer.
    Alam R; Carter HB; Landis P; Epstein JI; Mamawala M
    J Urol; 2015 Jun; 193(6):1950-5. PubMed ID: 25572035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
    Tosoian JJ; Loeb S; Feng Z; Isharwal S; Landis P; Elliot DJ; Veltri R; Epstein JI; Partin AW; Carter HB; Trock B; Sokoll LJ
    J Urol; 2012 Oct; 188(4):1131-6. PubMed ID: 22901577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?
    Satasivam P; Poon BY; Ehdaie B; Vickers AJ; Eastham JA
    J Urol; 2016 Jan; 195(1):74-9. PubMed ID: 26192258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multi-institutional evaluation of active surveillance for low risk prostate cancer.
    Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B
    J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
    Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
    J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
    Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
    J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
    Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
    J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.
    Patel HD; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
    J Urol; 2014 Mar; 191(3):629-37. PubMed ID: 24060641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic significance of perineural invasion and race in men considering active surveillance.
    Cohn JA; Dangle PP; Wang CE; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    BJU Int; 2014 Jul; 114(1):75-80. PubMed ID: 24106869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
    Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
    J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.
    Macleod LC; Ellis WJ; Newcomb LF; Zheng Y; Brooks JD; Carroll PR; Gleave ME; Lance RS; Nelson PS; Thompson IM; Wagner AA; Wei JT; Lin DW
    J Urol; 2017 Apr; 197(4):1026-1033. PubMed ID: 27810448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
    Bruinsma SM; Nieboer D; Roobol MJ; Bangma CH; Verbeek JFM; Gnanapragasam V; Van Hemelrijck M; Frydenberg M; Lee LS; Valdagni R; Logothetis C; Steyerberg EW;
    J Urol; 2021 Jul; 206(1):62-68. PubMed ID: 33617330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.
    Reese AC; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
    Urology; 2015 Nov; 86(5):991-5. PubMed ID: 26335496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.J Clin Oncol. 2015 Oct 20;33(30):3379-85. [Epub 2015 Aug 31]. doi: 10.1200/JCO.2015.62.5764.
    Scott E; Mamawala M; Epstein JI; Landis P; Wolf S; Trock ; Carter HB
    Urol Oncol; 2017 Mar; 35(3):121-122. PubMed ID: 28159497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
    Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
    Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
    Nyame YA; Grimberg DC; Greene DJ; Gupta K; Kartha GK; Berglund R; Gong M; Stephenson AJ; Magi-Galluzzi C; Klein EA
    J Urol; 2018 Feb; 199(2):438-444. PubMed ID: 28941920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.